MREO Key Statistics, Chart & Performance
The current stock price of MREO is 2.3 USD. In the past month the price increased by 28.49%. In the past year, price decreased by -38.34%.
MREO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.33 | 406.30B | ||
| AMGN | AMGEN INC | 15.27 | 179.83B | ||
| GILD | GILEAD SCIENCES INC | 15.34 | 155.92B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.67 | 117.47B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.41 | 82.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.67 | 52.94B | ||
| INSM | INSMED INC | N/A | 37.84B | ||
| NTRA | NATERA INC | N/A | 32.51B | ||
| BIIB | BIOGEN INC | 10.53 | 25.87B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.5 | 22.16B | ||
| INCY | INCYTE CORP | 15.64 | 19.72B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About MREO
Company Profile
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. The firm has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.
Company Info
MEREO BIOPHARMA GROUP PL-ADR
One Cavendish Place, Fourth Floor
London W1G0QF GB
CEO: Denise Scots-Knight
Employees: 36
Phone: 443330237300
MEREO BIOPHARMA GROUP PL-ADR / MREO FAQ
What does MEREO BIOPHARMA GROUP PL-ADR do?
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. The firm has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.
What is the current price of MREO stock?
The current stock price of MREO is 2.3 USD. The price increased by 0.44% in the last trading session.
What is the dividend status of MEREO BIOPHARMA GROUP PL-ADR?
MREO does not pay a dividend.
What is the ChartMill technical and fundamental rating of MREO stock?
MREO has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the employee count for MREO stock?
MEREO BIOPHARMA GROUP PL-ADR (MREO) currently has 36 employees.
What is the next earnings date for MREO stock?
MEREO BIOPHARMA GROUP PL-ADR (MREO) will report earnings on 2026-03-23, after the market close.
What is the ownership structure of MEREO BIOPHARMA GROUP PL-ADR (MREO)?
You can find the ownership structure of MEREO BIOPHARMA GROUP PL-ADR (MREO) on the Ownership tab.
MREO Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to MREO. When comparing the yearly performance of all stocks, MREO is a bad performer in the overall market: 77.49% of all stocks are doing better.
MREO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MREO. MREO has a great financial health rating, but its profitability evaluates not so good.
MREO Financial Highlights
Over the last trailing twelve months MREO reported a non-GAAP Earnings per Share(EPS) of -0.26. The EPS increased by 36.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -77.77% | ||
| ROE | -89.46% | ||
| Debt/Equity | 0 |
MREO Forecast & Estimates
15 analysts have analysed MREO and the average price target is 7.14 USD. This implies a price increase of 210.43% is expected in the next year compared to the current price of 2.3.